Aspire Biopharma Holdings Inc (NASDAQ: ASBP)’s stock price has increased by 18.97% compared to its previous closing price of $0.31. However, the company has seen a 20.16% increase in its stock price over the last five trading sessions. accessnewswire.com reported 2025-07-09 that Early positive consumer testimonials from initial Company product sampling Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect Completed initial production in four flavors Aspire to launch BUZZ BOMB™ at the FITCON and Fit Expo conventions in August ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / July 9, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced positive initial consumer feedback from the Company’s sampling of its sublingual pre-workout supplement, BUZZ BOMB™. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential.
Is It Worth Investing in Aspire Biopharma Holdings Inc (NASDAQ: ASBP) Right Now?
Additionally, the 36-month beta value for ASBP is 0.72.
The public float for ASBP is 39.39M and currently, short sellers hold a 1.71% ratio of that float. The average trading volume of ASBP on July 09, 2025 was 13.79M shares.
ASBP’s Market Performance
ASBP stock saw a decrease of 20.16% in the past week, with a monthly decline of -2.10% and a quarterly a decrease of -7.15%. The volatility ratio for the week is 12.00%, and the volatility levels for the last 30 days are 12.44% for Aspire Biopharma Holdings Inc (ASBP). The simple moving average for the last 20 days is 17.95% for ASBP stock, with a simple moving average of -94.08% for the last 200 days.
ASBP Trading at 10.17% from the 50-Day Moving Average
After a stumble in the market that brought ASBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.64% of loss for the given period.
Stock Fundamentals for ASBP
The total capital return value is set at 2.3. Equity return is now at value -490.07, with -234.69 for asset returns.
Based on Aspire Biopharma Holdings Inc (ASBP), the company’s capital structure generated -35.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at -0.97. The interest coverage ratio of the stock is -13.36.
Currently, EBITDA for the company is -11.65 million with net debt to EBITDA at -0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
In conclusion, Aspire Biopharma Holdings Inc (ASBP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
